title: Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study.
abstract: OBJECTIVE
  Widespread application of quantitative liver function tests as a prognostic tool is controversial. In this study we assessed the predictivity of serial evaluations of galactose elimination capacity (GEC) and the monoethylglycinexylidide (MEGX) test on survival in viral cirrhosis, and secondarily we compared these tests with Child-Turcotte-Pugh (CTP) and Model for End Stage Liver Disease (MELD) scores.
  
  
  METHODS
  In a cohort of 35 patients with viral cirrhosis, GEC and MEGX were evaluated every 6 months for 24 months and compared with CTP and MELD scores at the same time intervals. The end points were patient death or liver transplantation.
  
  
  RESULTS
  Statistically significant differences between dead/transplanted patients and survivors were found for basal values of GEC, MEGX, CTP and MELD. Receiver-operating characteristics curves of CTP and MELD scores showed a higher prognostic accuracy than GEC and MEGX. On multivariate analysis, neither GEC nor MEGX were independent predictors of survival. Repeated-measures analysis of GEC and MEGX did not increase the prognostic accuracy of these tests and did not add useful prognostic information on patient outcome during the following 6 months.
  
  
  CONCLUSIONS
  Our data suggest that neither single nor repeated determinations of GEC and MEGX are superior to CTP and MELD scores in predicting prognosis of patients with viral cirrhosis.
authors.affiliation: Unità Operativa Complessa di Epatologia, Azienda Ospedaliera A. Cardarelli, Napoli, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Addario
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Scaglione
authors.forename: Giovanni
authors.initials: G
authors.lastname: Tritto
authors.forename: Giovan Giuseppe
authors.initials: GG
authors.lastname: Di Costanzo
authors.forename: Massimo
authors.initials: M
authors.lastname: De Luca
authors.forename: Filippo
authors.initials: F
authors.lastname: Lampasi
authors.forename: Alfonso
authors.initials: A
authors.lastname: Galeota Lanza
authors.forename: Francesco P
authors.initials: FP
authors.lastname: Picciotto
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Tartaglione
authors.forename: Wanda
authors.initials: W
authors.lastname: Utech
authors.forename: Michela
authors.initials: M
authors.lastname: Macr
authors.forename: Eduardo
authors.initials: E
authors.lastname: Giannelli
authors.forename: Antonio
authors.initials: A
authors.lastname: Ascione
mesh_terms: D000328:Adult; D018450:Disease Progression; D004812:Epidemiologic Methods; D005260:Female; D005690:Galactose; D006525:Hepatitis, Viral, Human / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000503:physiopathology / Q000821:virology; D008111:Liver Function Tests / Q000379:methods*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012720:Severity of Illness Index
chemical_list: D008012:Lidocaine; C001173:monoethylglycinexylidide; D005690:Galactose